Changeflow GovPing Pharma & Drug Safety Carbohydrate Binding Module Variants and Hybrid...
Routine Notice Added Final

Carbohydrate Binding Module Variants and Hybrid Polypeptides Patent

Favicon for changeflow.com USPTO Patent Grants - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO granted Patent US12600996B2 to Novozymes A/S covering carbohydrate binding module variants and cellobiohydrolase variants. The patent includes 33 claims and covers polynucleotides encoding the variants, nucleic acid constructs, vectors, host cells, and associated methods. The filing date was July 13, 2022, under application number 17812259.

What changed

USPTO granted Patent US12600996B2 to Novozymes A/S for carbohydrate binding module variants and hybrid polypeptides. The patent contains 33 claims covering cellobiohydrolase variants, polynucleotides encoding these variants, and related nucleic acid constructs, vectors, and host cells.\n\nCompetitors developing enzyme products for industrial biotechnology applications involving carbohydrate binding should conduct freedom-to-operate analyses. Companies using similar enzyme engineering approaches may need to evaluate potential licensing requirements or design-around strategies to avoid infringement of the granted claims.

What to do next

  1. Monitor patent scope for freedom-to-operate analysis
  2. Review claims for potential licensing opportunities

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Carbohydrate binding module variants and hybrid polypeptides comprising same

Grant US12600996B2 Kind: B2 Apr 14, 2026

Assignee

Novozymes A/S

Inventors

Peter Westh, Kim Borch, Trine Soerensen, Michael Windahl, Brett McBrayer

Abstract

The present invention relates to cellobiohydrolase variants and carbohydrate binding module variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

CPC Classifications

C12P 19/14 C12P 5/02 C12P 7/14 C12P 7/16 C12P 7/18 C12P 7/20 C12P 19/02 C12P 2203/00 C12N 9/2437 C12N 15/8257 C12Y 302/01091 C07K 2319/00

Filing Date

2022-07-13

Application No.

17812259

Claims

33

View original document →

Get daily alerts for USPTO Patent Grants - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600996B2

Who this affects

Applies to
Pharmaceutical companies Manufacturers Investors
Industry sector
3254.1 Biotechnology
Activity scope
Patent grants Biotech research Enzyme development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!